Project Grant K01AI200492
- Federal Grant Award Summary Duke University's Office of Research Administration received a $806,623 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 29, 2026, with completion targeted for April 30, 2027. The research deliverables focus on elucidating the structural and kinetic mechanisms of HIV-1 broadly neutralizing antibody (bNAb) interactions, specifically...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $1,171,275 Project Grant awarded May 8, 2026, by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research deliverables focus on developing and evaluating a combined therapeutic countermeasure to achieve functional cure of HIV-1 infection through integration of two immunological approaches: a CD8 T cell...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $783,701 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 22, 2026 through April 30, 2031. The project investigates the development and contribution of individual plasma B cells to broad HIV serum neutralization, with the ultimate goal of advancing broadly neutralizing...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $208,875 Project Grant from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period August 1, 2025 through July 31, 2028. The grant supports research and development of a multivalent messenger ribonucleic acid (mRNA) HIV vaccine designed to elicit broadly neutralizing antibodies (BNAbs) targeting conserved...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Duke University a Project Grant valued at $106,164 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 1, 2026 through March 31, 2028. The award supports investigator-initiated research examining the role of HLA-E-VL9 (Human Leukocyte Antigen-E complexed with a conserved self-peptide) in HIV immune evasion and the therapeutic potential of naturally occurring...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $171,269 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective November 1, 2025, with completion targeted for April 30, 2028. This award funds investigator-initiated biomedical research to define the role of the RGS12 (Regulator of G-Protein Signaling 12) locus in macrophage function and...
- Federal Project Grant Summary Duke University's Office of Research Administration received a $237,831 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 22, 2026, through April 30, 2028. The award funds investigator-initiated biomedical research designed to elucidate the molecular mechanisms by which the cytosolic enzyme MESH1 regulates nucleotide metabolism and...
- Federal Grant Award Summary Duke University's Office of Research Administration was awarded $449,408 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project period from July 1, 2025 through June 30, 2027. The project focuses on developing diagnostic antibodies for acute and chronic Chagas disease, a neglected tropical disease caused by infection with the parasite Trypanosoma cruzi. The...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $1.66 million Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 1, 2026 through March 31, 2031. The award supports research aimed at discovering and optimizing broadly protective neutralizing antibodies against merbecviruses (MERBS), a family of Middle East Respiratory Syndrome...
- Federal Grant Award Summary The University of Florida's Division of Sponsored Research received a $402,150 Project Grant award dated July 23, 2025, from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research award, with a completion date of June 30, 2027, supports investigator-initiated biomedical research focused on understanding the viral mechanisms by which Kaposi's Sarcoma-Associated Herpesvirus...
Duke University's Office of Research Administration has been awarded $211,008 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a five-year research project from June 8, 2026 through May 31, 2031. The award supports investigator-initiated biomedical research examining antibody-mediated immune responses to Kaposi's Sarcoma-Associated Herpesvirus (KSHV) infection in immunocompromised populations. The research will utilize the rhesus macaque rhadinovirus (RRV)/rhesus macaque model to investigate how antibodies with Fc-receptor-mediated effector functions can suppress viral reactivation following simian immunodeficiency virus co-infection. The project deliverables include comparative analysis of antibody responses during primary RRV infection and reactivation, characterization of B cell maturation capacity to produce functionally active antibodies, and efficacy evaluations of these antibodies in immunocompromised animal models to prevent viral reactivation. This research addresses a critical knowledge gap regarding the role of Fc-mediated antibody effector functions in controlling KSHV, with potential applications for developing immune interventions to complement antiretroviral therapy in people living with HIV and other immunocompromised populations susceptible to KSHV-driven Kaposi's Sarcoma.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $211.0k | 6/9/26 |